Iradimed (IRMD) Common Equity (2013 - 2026)

Iradimed (IRMD) has 14 years of Common Equity data on file, last reported at $98.5 million in Q1 2026.

• Common Equity for Q1 2026 came in at $98.5 million, up 9.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $98.5 million (up 9.39% YoY), and the FY2025 annual result was $94.6 million, up 8.98% from the prior year.
• Common Equity climbed to $98.5 million in Q1 2026 per IRMD's latest filing, from $94.6 million in the prior quarter.
• Over five years, Common Equity peaked at $98.5 million in Q1 2026 and troughed at $62.5 million in Q1 2022.
• A 5-year average of $79.6 million and a median of $76.1 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2023 and 2024: Common Equity slipped 3.06% in 2023, then advanced 21.56% in 2024.
• A 5-year view of Common Equity shows it stood at $73.7 million in 2022, then slipped by 3.06% to $71.4 million in 2023, then climbed by 21.56% to $86.8 million in 2024, then grew by 8.98% to $94.6 million in 2025, then advanced by 4.12% to $98.5 million in 2026.
• Business Quant data shows IRMD's Common Equity at $98.5 million in Q1 2026, $94.6 million in Q4 2025, and $98.4 million in Q3 2025.